why choose us

First received: March 24, 2023

Clinical Trial: Cevostamab Following CAR T Cell Therapy for RRMM

Study Status: Completed

Recruit Status: RECRUITING

Condition: Relapsed/Refractory Multiple Myeloma

Study Type: INTERVENTIONAL


Official Title: Phase 2 Study of Cevostamab Consolidation Following BCMA CAR T Cell Therapy for Relapsed/Refractory Multiple Myeloma

Brief Summary: This is a Phase 2, open-label, single-arm, single stage, single-institution study, with an initial safety run-in period.Potential participants with relapsed/refractory myeloma who are undergoing standard of care, commercially-available BCMA-directed CAR T cell therapy may be identified pre-CAR T cell infusion but are not consented and enrolled until at least 4-6 weeks after CAR T cell infusion, once recovered from acute toxicities.Note: the lymphodepleting chemotherapy and CAR T cell therapy is being…

Read more